Protocol Details
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
This study is currently recruiting participants.
Summary
Number | 000079-DK |
Sponsoring Institute | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Recruitment Detail | Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 98 Years |
Referral Letter Required | No |
Population Exclusion(s) | Children |
Keywords | Thyroid Cancer;
Metastases;
Ga68-DOTATATE;
Somatostatin Receptors;
Positron Emission Tomography |
Recruitment Keyword(s) | None |
Condition(s) | metastic thyroid cancer |
Investigational Drug(s) | 68Gallium-Dotatate
|
Investigational Device(s) | None |
Intervention(s) | Drug: 68-Gallium-DOTATATE-PET/CT
|
Supporting Site | National Institute of Diabetes and Digestive and Kidney Diseases |
Background:
About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can better detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to a tumor and make it visible during a positron emission tomography/computed tomography (PET/CT) scan. This information might help guide future research and treatment.
Objective:
To identify the people with thyroid cancer whose tumors have a high uptake of 68Gallium-DOTATATE as analyzed by imaging with PET/CT.
Eligibility:
People ages 18 years and older with thyroid cancer that has spread outside of the thyroid.
Design:
Participants will have a medical exam. They will give blood and urine samples. Some samples will be used for research.
Participants will have imaging scans that follow standard of care. These scans may include:
CT scan of the neck, chest, abdomen, and pelvis
Bone scan
Magnetic resonance imaging of the brain, spine, or liver
18-FDG-PET/CT as needed
Participants will have a PET/CT scan. They will get an intravenous (IV) line. They will get an IV injection of 68Gallium-DOTATATE. It contains radioactive tracers. The PET/CT scanner is shaped like a large donut. It contains crystals. The crystals pick up small radiation signals that are given off by the tracers. The CT part of the scan uses low-dose x-rays. The pictures made by the scanner show where the tracers are in the body. The session will last 90 minutes.
Participation will last for about 3 months.
Eligibility
INCLUSION CRITERIA:
Data prospectively collected from the 28 subjects enrolled under this protocol, and data from 26 subjects collected under 77-DK-0096 and/or 00-CH-0093 will be analyzed. Among the 26 subjects prospectively evaluated under 77-DK-0096 protocol, 21 out of 26 had research 68Ga-DOTATATE PET/CT performed under the DOTATATE sub-study of 77-DK-0096, and 5 out of 26 had 68Ga-DOTATATE PET/CT done under 00-CH-0093. Again, the inclusion of the above data was per the IRB s request to transition the sub-study into a new standalone protocol. This will give us a total of 54 subjects for the final analyses, with at least 18 subjects from each group (e.g., HTC, DTC, and MTC), which is required to meet the primary objectives of this study with sufficient power of 80% and type 1 error alpha of < 0.05.
Patients with HTC, DTC, and MTC will be identified by the investigators. The potential candidates for the study will be screened for eligibility to participate in the study and invited to sign the Research 68Ga-DOTATATE PET/CT imaging informed consent form. The same inclusion/exclusion criteria were applied to the subjects who underwent imaging with the 68GADOTATATE PET/CT, either under the 77-DK-0096 sub-study or as clinically-indicated imaging under 00-CH-0093.
In order to be eligible to participate in this study, an individual with DTC (including HTC) must meet all of the following criteria:
-Male or female, aged >18 years.
-Patients with established thyroid cancer diagnosis presenting with either:
--Locally advanced or distant metastases, which are RAI-non-avid based on the or diagnostic or post-treatment whole body scan (WBS)
OR
--Patients with RAI-non-responsive disease, who have the evidence of disease progression defined by RECIST 1.1 criteria after therapy with RAI.
In order to be eligible to participate in this study, an individual with MTC must meet all of the following criteria:
-Male or female, aged >18 years.
-Patients with locally advanced or metastatic MTC or patients suspected of locally advanced or metastatic MTC with calcitonin level > 500 pg/mL.
EXCLUSION CRITERIA:
Subjects with either HTC, DTC, or MTC who meet any of the following criteria will be excluded from participation in this study:
-Pregnancy or lactation by self-report.
-Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma;
-Patients unable to give informed consent.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT04927416